Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$108.50
-1.80-1.63%
At close: -
$108.50
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Jazz Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:JAZZ | Benzinga
Jazz Pharmaceuticals PLC has a consensus price target of $189.3 based on the ratings of 21 analysts. The high is $230 issued by Truist Securities on March 6, 2025. The low is $147 issued by Piper Sandler on May 7, 2025. The 3 most-recent analyst ratings were released by Needham, Needham, and Baird on June 11, 2025, June 3, 2025, and May 7, 2025, respectively. With an average price target of $186.33 between Needham, Needham, and Baird, there's an implied 71.74% upside for Jazz Pharmaceuticals PLC from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
Baird
RBC Capital
Piper Sandler
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Jazz Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/11/2025 | Buy Now | 86.18% | Needham | Ami Fadia61% | $202 → $202 | Reiterates | Buy → Buy | Get Alert |
| 06/03/2025 | Buy Now | 86.18% | Needham | Ami Fadia61% | $202 → $202 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2025 | Buy Now | 42.86% | Baird | Joel Beatty69% | $167 → $155 | Maintains | Outperform | Get Alert |
| 05/07/2025 | Buy Now | 58.53% | RBC Capital | Gregory Renza52% | $182 → $172 | Maintains | Outperform | Get Alert |
| 05/07/2025 | Buy Now | 35.48% | Piper Sandler | David Amsellem74% | $176 → $147 | Reiterates | Overweight → Overweight | Get Alert |
| 05/07/2025 | Buy Now | 53% | Morgan Stanley | Jeffrey Hung52% | $183 → $166 | Maintains | Overweight | Get Alert |
| 05/07/2025 | Buy Now | 84.33% | Needham | Ami Fadia61% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2025 | Buy Now | 93.55% | Needham | Ami Fadia61% | $210 → $210 | Reiterates | Buy → Buy | Get Alert |
| 03/10/2025 | Buy Now | 100% | HC Wainwright & Co. | Oren Livnat61% | $200 → $217 | Maintains | Buy | Get Alert |
| 03/07/2025 | Buy Now | 68.66% | Morgan Stanley | Jeffrey Hung52% | $175 → $183 | Assumes | → Overweight | Get Alert |
| 03/07/2025 | Buy Now | 64.98% | UBS | Ashwani Verma48% | $145 → $179 | Upgrade | Neutral → Buy | Get Alert |
| 03/06/2025 | Buy Now | 111.98% | Truist Securities | Gregory Fraser63% | $220 → $230 | Maintains | Buy | Get Alert |
| 03/05/2025 | Buy Now | 93.55% | Needham | Ami Fadia61% | $210 → $210 | Reiterates | Buy → Buy | Get Alert |
| 02/27/2025 | Buy Now | 84.33% | Barclays | Balaji Prasad56% | $190 → $200 | Maintains | Overweight | Get Alert |
| 02/26/2025 | Buy Now | 38.25% | Cantor Fitzgerald | Charles Duncan69% | $140 → $150 | Downgrade | Overweight → Neutral | Get Alert |
| 02/26/2025 | Buy Now | 62.21% | Piper Sandler | David Amsellem74% | $163 → $176 | Reiterates | Overweight → Overweight | Get Alert |
| 02/26/2025 | Buy Now | 64.06% | RBC Capital | Gregory Renza52% | $179 → $178 | Maintains | Outperform | Get Alert |
| 02/26/2025 | Buy Now | 92.63% | JP Morgan | Jessica Fye66% | $200 → $209 | Maintains | Overweight | Get Alert |
| 02/26/2025 | Buy Now | 93.55% | Needham | Ami Fadia61% | $205 → $210 | Maintains | Buy | Get Alert |
| 02/13/2025 | Buy Now | 56.68% | Wells Fargo | Mohit Bansal68% | $130 → $170 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 12/12/2024 | Buy Now | 50.23% | Piper Sandler | David Amsellem74% | $163 → $163 | Reiterates | Overweight → Overweight | Get Alert |
| 12/12/2024 | Buy Now | 64.98% | RBC Capital | Gregory Renza52% | $179 → $179 | Reiterates | Outperform → Outperform | Get Alert |
| 12/12/2024 | Buy Now | 90.78% | Needham | Ami Fadia61% | $207 → $207 | Reiterates | Buy → Buy | Get Alert |
| 12/10/2024 | Buy Now | 64.98% | RBC Capital | Gregory Renza52% | $179 → $179 | Reiterates | Outperform → Outperform | Get Alert |
| 11/22/2024 | Buy Now | 84.33% | HC Wainwright & Co. | Oren Livnat61% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 11/21/2024 | Buy Now | 90.78% | Needham | Ami Fadia61% | $207 → $207 | Reiterates | Buy → Buy | Get Alert |
| 11/21/2024 | Buy Now | 50.23% | Piper Sandler | David Amsellem74% | $166 → $163 | Reiterates | Overweight → Overweight | Get Alert |
| 11/18/2024 | Buy Now | 49.31% | Baird | Joel Beatty69% | $154 → $162 | Maintains | Outperform | Get Alert |
| 11/07/2024 | Buy Now | 79.72% | TD Cowen | — | $200 → $195 | Maintains | Buy | Get Alert |
| 11/07/2024 | Buy Now | 90.78% | Needham | Ami Fadia61% | $207 → $207 | Reiterates | Buy → Buy | Get Alert |
| 10/23/2024 | Buy Now | 64.98% | RBC Capital | Gregory Renza52% | $175 → $179 | Maintains | Outperform | Get Alert |
| 10/04/2024 | Buy Now | 61.29% | RBC Capital | Gregory Renza52% | $174 → $175 | Maintains | Outperform | Get Alert |
| 09/10/2024 | Buy Now | 88.94% | Needham | Ami Fadia61% | $205 → $205 | Reiterates | Buy → Buy | Get Alert |
| 09/09/2024 | Buy Now | 29.03% | Cantor Fitzgerald | Charles Duncan69% | $140 → $140 | Reiterates | Overweight → Overweight | Get Alert |
| 08/19/2024 | Buy Now | 86.18% | JP Morgan | Jessica Fye66% | $190 → $202 | Maintains | Overweight | Get Alert |
| 08/01/2024 | Buy Now | 29.03% | Cantor Fitzgerald | Charles Duncan69% | $140 → $140 | Reiterates | Overweight → Overweight | Get Alert |
| 08/01/2024 | Buy Now | 53% | Piper Sandler | David Amsellem74% | $188 → $166 | Maintains | Overweight | Get Alert |
| 08/01/2024 | Buy Now | 60.37% | RBC Capital | Gregory Renza52% | $175 → $174 | Maintains | Outperform | Get Alert |
| 08/01/2024 | Buy Now | 10.6% | Wells Fargo | Mohit Bansal68% | $140 → $120 | Maintains | Equal-Weight | Get Alert |
| 08/01/2024 | Buy Now | 88.94% | Needham | Ami Fadia61% | $208 → $205 | Maintains | Buy | Get Alert |
| 08/01/2024 | Buy Now | 84.33% | HC Wainwright & Co. | Oren Livnat61% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2024 | Buy Now | 41.94% | Baird | Joel Beatty69% | $160 → $154 | Maintains | Outperform | Get Alert |
| 07/12/2024 | Buy Now | 38.25% | Morgan Stanley | Jeffrey Hung52% | $160 → $150 | Maintains | Equal-Weight | Get Alert |
| 07/02/2024 | Buy Now | 4.15% | UBS | Ashwani Verma48% | $117 → $113 | Maintains | Neutral | Get Alert |
| 06/20/2024 | Buy Now | 93.55% | Needham | Ami Fadia61% | $222 → $210 | Maintains | Buy | Get Alert |
| 06/05/2024 | Buy Now | 55.76% | Goldman Sachs | Madhu Kumar72% | → $169 | Initiates | → Buy | Get Alert |
| 05/03/2024 | Buy Now | 84.33% | HC Wainwright & Co. | Oren Livnat61% | $200 → $200 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2024 | Buy Now | 84.33% | Barclays | Balaji Prasad56% | $230 → $200 | Maintains | Overweight | Get Alert |
| 05/02/2024 | Buy Now | 104.61% | Needham | Ami Fadia61% | $222 → $222 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | Buy Now | 65.9% | Cantor Fitzgerald | Charles Duncan69% | $180 → $180 | Reiterates | Overweight → Overweight | Get Alert |
| 03/22/2024 | Buy Now | 65.9% | Cantor Fitzgerald | Charles Duncan69% | $180 → $180 | Reiterates | Overweight → Overweight | Get Alert |
| 03/22/2024 | Buy Now | 75.12% | JP Morgan | Jessica Fye66% | $170 → $190 | Maintains | Overweight | Get Alert |
| 03/20/2024 | Buy Now | 102.76% | Needham | Ami Fadia61% | $220 → $220 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2024 | Buy Now | 84.33% | Truist Securities | Joon Lee77% | → $200 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2024 | Buy Now | 73.27% | Piper Sandler | David Amsellem74% | $171 → $188 | Reiterates | Overweight → Overweight | Get Alert |
| 03/15/2024 | Buy Now | 111.98% | Stifel | Annabel Samimy66% | $225 → $230 | Maintains | Buy | Get Alert |
| 03/14/2024 | Buy Now | 84.33% | HC Wainwright & Co. | Oren Livnat61% | $204 → $200 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | 111.98% | Barclays | Balaji Prasad56% | $235 → $230 | Maintains | Overweight | Get Alert |
| 03/01/2024 | Buy Now | 20.74% | UBS | Ashwani Verma48% | $135 → $131 | Maintains | Neutral | Get Alert |
| 02/29/2024 | Buy Now | 79.72% | RBC Capital | Gregory Renza52% | $195 → $195 | Reiterates | Outperform → Outperform | Get Alert |
| 02/29/2024 | Buy Now | 65.9% | Cantor Fitzgerald | Charles Duncan69% | $180 → $180 | Reiterates | Overweight → Overweight | Get Alert |
| 02/29/2024 | Buy Now | 56.68% | JP Morgan | Jessica Fye66% | $180 → $170 | Maintains | Overweight | Get Alert |
| 02/29/2024 | Buy Now | 102.76% | Needham | Ami Fadia61% | $225 → $220 | Maintains | Buy | Get Alert |
| 01/29/2024 | Buy Now | 116.59% | Barclays | Balaji Prasad56% | $240 → $235 | Maintains | Overweight | Get Alert |
| 01/03/2024 | Buy Now | 47.47% | Baird | Joel Beatty69% | → $160 | Initiates | → Outperform | Get Alert |
| 12/04/2023 | Buy Now | 84.33% | Truist Securities | Joon Lee77% | → $200 | Reiterates | Buy → Buy | Get Alert |
| 11/29/2023 | Buy Now | 107.37% | Needham | Ami Fadia61% | → $225 | Reiterates | Buy → Buy | Get Alert |
| 11/27/2023 | Buy Now | 24.42% | UBS | Ashwani Verma48% | $170 → $135 | Downgrade | Buy → Neutral | Get Alert |
| 11/09/2023 | Buy Now | 76.04% | RBC Capital | Gregory Renza52% | $200 → $191 | Maintains | Outperform | Get Alert |
| 11/09/2023 | Buy Now | 107.37% | Needham | Ami Fadia61% | $226 → $225 | Maintains | Buy | Get Alert |
| 09/29/2023 | Buy Now | — | Raymond James | Gary Nachman61% | — | Initiates | → Market Perform | Get Alert |
| 08/22/2023 | Buy Now | 65.9% | Cantor Fitzgerald | Brandon Folkes44% | → $180 | Reiterates | Overweight → Overweight | Get Alert |
| 08/14/2023 | Buy Now | 65.9% | Cantor Fitzgerald | Brandon Folkes44% | $210 → $180 | Maintains | Overweight | Get Alert |
| 08/11/2023 | Buy Now | 88.02% | HC Wainwright & Co. | Oren Livnat61% | → $204 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 100% | B of A Securities | Jason Gerberry64% | $204 → $217 | Maintains | Buy | Get Alert |
| 08/10/2023 | Buy Now | 85.25% | RBC Capital | Gregory Renza52% | $203 → $201 | Maintains | Outperform | Get Alert |
| 08/10/2023 | Buy Now | 108.29% | Needham | Ami Fadia61% | → $226 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | 108.29% | Needham | Ami Fadia61% | → $226 | Reiterates | Buy → Buy | Get Alert |
| 07/11/2023 | Buy Now | 72.35% | Morgan Stanley | Jeffrey Hung52% | $187 → $187 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/05/2023 | Buy Now | 108.29% | Needham | Ami Fadia61% | → $226 | Reiterates | Buy → Buy | Get Alert |
| 05/30/2023 | Buy Now | 108.29% | Needham | Ami Fadia61% | $212 → $226 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 88.02% | HC Wainwright & Co. | Oren Livnat61% | → $204 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 95.39% | Needham | Ami Fadia61% | → $212 | Reiterates | Buy → Buy | Get Alert |
| 05/11/2023 | Buy Now | 86.18% | RBC Capital | Gregory Renza52% | $207 → $202 | Maintains | Outperform | Get Alert |
| 05/11/2023 | Buy Now | 95.39% | Needham | Ami Fadia61% | $205 → $212 | Maintains | Buy | Get Alert |
| 03/06/2023 | Buy Now | 88.02% | HC Wainwright & Co. | Oren Livnat61% | → $204 | Reiterates | → Buy | Get Alert |
| 03/03/2023 | Buy Now | 95.39% | Goldman Sachs | Madhu Kumar72% | $190 → $212 | Maintains | Buy | Get Alert |
| 03/02/2023 | Buy Now | 88.94% | Needham | Ami Fadia61% | $210 → $205 | Maintains | Buy | Get Alert |
| 12/09/2022 | Buy Now | 75.12% | Goldman Sachs | Madhu Kumar72% | $192 → $190 | Upgrade | Neutral → Buy | Get Alert |
| 11/10/2022 | Buy Now | 76.96% | Goldman Sachs | Madhu Kumar72% | $170 → $192 | Maintains | Neutral | Get Alert |
| 11/10/2022 | Buy Now | 90.78% | RBC Capital | Gregory Renza52% | $206 → $207 | Maintains | Outperform | Get Alert |
| 11/10/2022 | Buy Now | 91.71% | Needham | Ami Fadia61% | $210 → $208 | Maintains | Buy | Get Alert |
| 09/29/2022 | Buy Now | 56.68% | Goldman Sachs | Madhu Kumar72% | $148 → $170 | Maintains | Neutral | Get Alert |
| 09/21/2022 | Buy Now | 36.41% | Goldman Sachs | Madhu Kumar72% | $192 → $148 | Maintains | Neutral | Get Alert |
| 08/04/2022 | Buy Now | 73.27% | BMO Capital | Gary Nachman61% | $185 → $188 | Maintains | Outperform | Get Alert |
| 08/04/2022 | Buy Now | 72.35% | Morgan Stanley | Jeffrey Hung52% | $174 → $187 | Maintains | Equal-Weight | Get Alert |
| 08/04/2022 | Buy Now | 76.04% | UBS | Ashwani Verma48% | $194 → $191 | Maintains | Buy | Get Alert |
| 08/04/2022 | Buy Now | 93.55% | SVB Leerink | Marc Goodman73% | $200 → $210 | Maintains | Outperform | Get Alert |
| 06/14/2022 | Buy Now | 78.8% | UBS | Ashwani Verma48% | → $194 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Jazz Pharmaceuticals (JAZZ) stock?
The latest price target for Jazz Pharmaceuticals (NASDAQ:JAZZ) was reported by Needham on June 11, 2025. The analyst firm set a price target for $202.00 expecting JAZZ to rise to within 12 months (a possible 86.18% upside). 45 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Jazz Pharmaceuticals (JAZZ)?
The latest analyst rating for Jazz Pharmaceuticals (NASDAQ:JAZZ) was provided by Needham, and Jazz Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Jazz Pharmaceuticals (JAZZ)?
The last upgrade for Jazz Pharmaceuticals PLC happened on March 7, 2025 when UBS raised their price target to $179. UBS previously had a neutral for Jazz Pharmaceuticals PLC.
When was the last downgrade for Jazz Pharmaceuticals (JAZZ)?
The last downgrade for Jazz Pharmaceuticals PLC happened on February 26, 2025 when Cantor Fitzgerald changed their price target from $140 to $150 for Jazz Pharmaceuticals PLC.
When is the next analyst rating going to be posted or updated for Jazz Pharmaceuticals (JAZZ)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jazz Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jazz Pharmaceuticals was filed on June 11, 2025 so you should expect the next rating to be made available sometime around June 11, 2026.
Is the Analyst Rating Jazz Pharmaceuticals (JAZZ) correct?
While ratings are subjective and will change, the latest Jazz Pharmaceuticals (JAZZ) rating was a reiterated with a price target of $202.00 to $202.00. The current price Jazz Pharmaceuticals (JAZZ) is trading at is $108.50, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
